Clinical Trial Details
| Trial ID: | L4500 |
| Source ID: | NCT03105219 |
| Associated Drug: | Ivabradine |
| Title: | IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease |
| Acronym: | BENCH |
| Status: | WITHDRAWN |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetic Kidney Disease |
| Interventions: | DRUG: Ivabradine|OTHER: Sham Comparator |
| Outcome Measures: | Primary: Urinary albumin excretion, Urinary albumin excretion at 3 month, 3 month | Secondary: Serum creatinine, Serum creatinine at 3 month, 3 month|Blood urea nitrogen, Blood urea nitrogen at 3 month, 3 month|Cyscatin-c, Cyscatin-c at 3 month, 3 month|Hypersensitive c-reactive protein (hsCRP), Hypersensitive c-reactive protein (hsCRP) at 3 month, 3 month|β2-microglobulin, β2-microglobulin at 3 month, 3 month|Neutrophil gelatinase-associated lipocalin(NGAL), Neutrophil gelatinase-associated lipocalin(NGAL) at 3 month, 3 month|Albuminuria and urine creatinine ratio (ACR), Albuminuria and urine creatinine ratio (ACR) at 3 month, 3 month|N-acyl-β-D-glucosidase, N-acyl-β-D-glucosidase at 3 month, 3 month|Retinol binding protein, Retinol binding protein at 3 month, 3 month |
| Sponsor/Collaborators: | Sponsor: Nanjing First Hospital, Nanjing Medical University |
| Gender: | ALL |
| Age: | CHILD, ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 0 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT |
| Start Date: | 2017-07-01 |
| Completion Date: | 2021-05-30 |
| Results First Posted: | |
| Last Update Posted: | 2020-11-09 |
| Locations: | Nanjing First Hospital, Nanjing, Jiangsu, 210006, China |
| URL: | https://clinicaltrials.gov/show/NCT03105219 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|